Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?

References

• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–348. doi:10.1056/NEJMsa1311707
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683–693. doi:10.1053/j.seminoncol.2012.09.005
   PubMed Web of Science ®Google Scholar
• Clift RA, Hansen JA, Thomas ED, et al. Marrow transplantation from donors other than HLA-identical siblings. Transplantation. 1979;28(3):235–242. doi:10.1097/00007890-197909000-00016
   PubMed Web of Science ®Google Scholar
• Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765–771. doi:10.1056/NEJM198509263131301
   PubMed Web of Science ®Google Scholar
• Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;1(8325):612–615.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320(4):197–204. doi:10.1056/NEJM198901263200401
   PubMed Web of Science ®Google Scholar
• Ghimire S, Weber D, Mavin E, et al. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol. 2017;8:79. doi:10.3389/fimmu.2017.01454
   PubMed Web of Science ®Google Scholar
• Reisner Y, Itzicovitch L, Meshorer A, et al. Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci USA. 1978;75(6):2933–2936. doi:10.1073/pnas.75.6.2933
   PubMed Web of Science ®Google Scholar
• Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61(2):341–348. doi:10.1182/blood.V61.2.341.341
   PubMed Web of Science ®Google Scholar
• Reisner Y, Kapoor N, O'Reilly RJ, et al. Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet. 1980;2(8208–8209):1320–1324.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Hamadani M, Wu J, et al. Post-Transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338–2348. doi:10.1056/NEJMoa2215943
   PubMed Web of Science ®Google Scholar
• Roldan E, Perales MA, Barba P. Allogeneic stem cell transplantation with CD34+ cell selection. Clin Hematol Int. 2019;1(3):154–160.
   PubMedGoogle Scholar
• Papadimitriou CA, Roots A, Koenigsmann M, et al. Immunomagnetic selection of CD34 + cells from fresh peripheral blood mononuclear cell preparations using two different separation techniques. J Hematother. 1995;4(6):539–544. doi:10.1089/scd.1.1995.4.539
   PubMedGoogle Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186–1193. doi:10.1056/NEJM199810223391702
   PubMed Web of Science ®Google Scholar
• Dvorak CC, Gilman AL, Horn B, et al. Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose. Bone Marrow Transplant. 2013;48(4):508–513. doi:10.1038/bmt.2012.186
   PubMed Web of Science ®Google Scholar
• Goldberg JD, Linker A, Kuk D, et al. T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(2):208–213. doi:10.1016/j.bbmt.2012.09.003
   PubMed Web of Science ®Google Scholar
• Hobbs GS, Hamdi A, Hilden PD, et al. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant. 2015;50(4):493–498. doi:10.1038/bmt.2014.302
   PubMed Web of Science ®Google Scholar
• Keever-Taylor CA, Devine SM, Soiffer RJ, et al. Characteristics of CliniMACS(R) system CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-blood and marrow transplant clinical trials network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012;18(5):690–697. doi:10.1016/j.bbmt.2011.08.017
   PubMed Web of Science ®Google Scholar
• Barba P, Martino R, Zhou Q, et al. CD34(+) cell selection versus reduced-intensity conditioning and unmodified grafts for allogeneic hematopoietic cell transplantation in patients age >50 years with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24(5):964–972. doi:10.1016/j.bbmt.2017.12.804
   PubMed Web of Science ®Google Scholar
• Tamari R, Oran B, Hilden P, et al. Allogeneic stem cell transplantation for advanced myelodysplastic syndrome: comparison of outcomes between CD34(+) selected and unmodified hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(5):1079–1087. doi:10.1016/j.bbmt.2018.01.001
   PubMed Web of Science ®Google Scholar
• Luznik L, Pasquini MC, Logan B, et al. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2022;40(4):356–368. doi:10.1200/JCO.21.02293
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100. doi:10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Barfield RC, Otto M, Houston J, et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy. 2004;6(1):1–6. doi:10.1080/14653240310004411
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Chen X, Pfeiffer M, et al. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci. 2007;1106:279–289. doi:10.1196/annals.1392.022
   PubMed Web of Science ®Google Scholar
• Bader P, Soerensen J, Jarisch A, et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. Best Pract Res Clin Haematol. 2011;24(3):331–337. doi:10.1016/j.beha.2011.04.005
   PubMed Web of Science ®Google Scholar
• Dufort G, Pisano S, Incoronato A, et al. Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay. Bone Marrow Transplant. 2012;47(5):663–668. doi:10.1038/bmt.2011.148
   PubMed Web of Science ®Google Scholar
• Perez-Martinez A, Gonzalez-Vicent M, Valentin J, et al. Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplant. 2012;47(11):1419–1427. doi:10.1038/bmt.2012.43
   PubMed Web of Science ®Google Scholar
• Leung W, Campana D, Yang J, et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood. 2011;118(2):223–230. doi:10.1182/blood-2011-01-333070
   PubMed Web of Science ®Google Scholar
• Eissens DN, Schaap NP, Preijers FW, et al. CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia. 2010;24(3):583–591. doi:10.1038/leu.2009.269
   PubMed Web of Science ®Google Scholar
• Federmann B, Bornhauser M, Meisner C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica. 2012;97(10):1523–1531. doi:10.3324/haematol.2011.059378
   PubMed Web of Science ®Google Scholar
• Chen BJ, Deoliveira D, Cui X, et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood. 2007;109(7):3115–3123. doi:10.1182/blood-2006-04-016410
   PubMed Web of Science ®Google Scholar
• Drobyski WR, Majewski D, Hanson G. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5(4):222–230. doi:10.1053/bbmt.1999.v5.pm10465102
   PubMedGoogle Scholar
• Lamb LJ, Musk P, Ye Z, et al. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 2001;27(6):601–606. doi:10.1038/sj.bmt.1702830
   PubMed Web of Science ®Google Scholar
• Scheper W, van Dorp S, Kersting S, et al. Gammadelta t cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia. 2013;27(6):1328–1338. doi:10.1038/leu.2012.374
   PubMed Web of Science ®Google Scholar
• Fujishima N, Hirokawa M, Fujishima M, et al. Skewed T cell receptor repertoire of Vdelta1(+) gammadelta T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction. Clin Exp Immunol. 2007;149(1):70–79. doi:10.1111/j.1365-2249.2007.03388.x
   PubMed Web of Science ®Google Scholar
• Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007;39(12):751–757. doi:10.1038/sj.bmt.1705650
   PubMed Web of Science ®Google Scholar
• Schumm M, Lang P, Bethge W, et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy. 2013;15(10):1253–1258. doi:10.1016/j.jcyt.2013.05.014
   PubMed Web of Science ®Google Scholar
• Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alpha beta+ T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–826. doi:10.1182/blood-2014-03-563817
   PubMed Web of Science ®Google Scholar
• Locatelli F, Merli P, Pagliara D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alpha beta T-cell and B-cell depletion. Blood. 2017;130(5):677–685. doi:10.1182/blood-2017-04-779769
   PubMed Web of Science ®Google Scholar
• Pulsipher MA, Ahn KW, Bunin NJ, et al. KIR-favorable TCR-alphabeta/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. Blood. 2022;140(24):2556–2572. doi:10.1182/blood.2022015959
   PubMed Web of Science ®Google Scholar
• Bethge WA, Eyrich M, Mielke S, et al. Results of a multicenter phase I/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bone Marrow Transplant. 2022;57(3):423–430. doi:10.1038/s41409-021-01551-z
   PubMed Web of Science ®Google Scholar
• Diaz MA, Zubicaray J, Molina B, et al. Haploidentical stem cell transplantation in children with hematological malignancies using alphabeta(+) T-cell receptor and CD19(+) cell depleted grafts: high CD56(dim)/CD56(bright) NK cell ratio early following transplantation is associated with lower relapse incidence and better outcome. Front Immunol. 2019;10:2504. doi:10.3389/fimmu.2019.02504
   PubMed Web of Science ®Google Scholar
• Airoldi I, Bertaina A, Prigione I, et al. Gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+/CD19 + lymphocytes. Blood. 2015;125(15):2349–2358. doi:10.1182/blood-2014-09-599423
   PubMed Web of Science ®Google Scholar
• Tumino N, Besi F, Di Pace AL, et al. PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. Leukemia. 2020;34(3):932–937. doi:10.1038/s41375-019-0585-7
   PubMed Web of Science ®Google Scholar
• Stocker N, Gaugler B, Labopin M, et al. High-dose post-transplant cyclophosphamide impairs gammadelta T-cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft. Clin Transl Immunology. 2020;9(9):e1171. doi:10.1002/cti2.1171
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(12):1835–1844. doi:10.1016/j.bbmt.2012.07.003.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20(12):1975–1981. doi:10.1016/j.bbmt.2014.08.013
   PubMed Web of Science ®Google Scholar
• Bertaina A, Zorzoli A, Petretto A, et al. Zoledronic acid boosts gammadelta T-cell activity in children receiving alphabeta(+) T and CD19(+) cell-depleted grafts from an HLA-haplo-identical donor. Oncoimmunology. 2017;6(2):e1216291. doi:10.1080/2162402X.2016.1216291
   PubMed Web of Science ®Google Scholar
• Merli P, Algeri M, Galaverna F, et al. Immune modulation properties of zoledronic acid on TcRgammadelta T-lymphocytes after TcRalphabeta/CD19-depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia. Front Immunol. 2020;11:699. doi:10.3389/fimmu.2020.00699
   PubMed Web of Science ®Google Scholar
• Bleakley M, Sehgal A, Seropian S, et al. Naive T-cell depletion to prevent chronic graft-versus-host disease. J Clin Oncol. 2022;40(11):1174–1185. doi:10.1200/JCO.21.01755
   PubMed Web of Science ®Google Scholar
• O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–386. doi:10.1053/bbmt.2002.v8.pm12171484
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–1040. doi:10.1182/blood-2015-04-639831
   PubMed Web of Science ®Google Scholar
• Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938–947. doi:10.1182/blood-2015-09-671834
   PubMed Web of Science ®Google Scholar
• Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18(12):1859–1866. doi:10.1016/j.bbmt.2012.06.019
   PubMed Web of Science ®Google Scholar
• Solomon SR, Sizemore CA, Sanacore M, et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21(7):1299–1307. doi:10.1016/j.bbmt.2015.03.003
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Labopin M, Brissot E, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021;193(3):592–601. doi:10.1111/bjh.17426
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Labopin M, Bazarbachi A, et al. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the acute leukemia working party of EBMT. Bone Marrow Transplant. 2021;56(9):2194–2202. doi:10.1038/s41409-021-01317-7
   PubMed Web of Science ®Google Scholar
• Mohty R, Brissot E, Battipaglia G, et al. Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation. Br J Haematol. 2019;187(3):e64–ee8.
   PubMed Web of Science ®Google Scholar
• Fayard A, Daguenet E, Blaise D, et al. Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Bone Marrow Transplant. 2019;54(10):1586–1594. doi:10.1038/s41409-019-0475-7
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Roth-Guepin G, Battipaglia G, et al. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. Transpl Infect Dis. 2015;17(6):822–830. doi:10.1111/tid.12455
   PubMed Web of Science ®Google Scholar
• Dulery R, Mohty R, Labopin M, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 2021;3(2):250–259. doi:10.1016/j.jaccao.2021.02.011
   PubMedGoogle Scholar
• Wachsmuth LP, Patterson MT, Eckhaus MA, et al. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129(6):2357–2373. doi:10.1172/JCI124218
   PubMed Web of Science ®Google Scholar
• McAdams MJ, Hyder M, Dimitrova D, et al. Phase I/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation. Blood. 2021;138:101. doi:10.1182/blood-2021-146997
   Google Scholar
• Ippoliti G, Lucioni M, Leonardi G, et al. Immunomodulation with rabbit anti-thymocyte globulin in solid organ transplantation. World J Transplant. 2015;5(4):261–266. doi:10.5500/wjt.v5.i4.261
   PubMedGoogle Scholar
• Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4 + CD25 + Foxp3 + regulatory T cells. J Am Soc Nephrol. 2006;17(10):2844–2853. doi:10.1681/ASN.2006050422
   PubMed Web of Science ®Google Scholar
• Chung DT, Korn T, Richard J, et al. Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3 + regulatory T cells. Int Immunol. 2007;19(8):1003–1010. doi:10.1093/intimm/dxm078
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387–1394. doi:10.1038/sj.leu.2404683
   PubMed Web of Science ®Google Scholar
• Piekarska A, Czyz A, Peczynski C, et al. ATG or no ATG? – survey of clinical practice in EBMT centers on behalf of the Transplant Complications Working Party of EBMT. Bone Marrow Transplant. 2023;58(3):337–339. doi:10.1038/s41409-022-01889-y
   PubMed Web of Science ®Google Scholar
• Xu ZL, Huang XJ. Haploidentical transplants with a G-CSF/ATG-based protocol: experience from China. Blood Rev. 2022: 101035.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Bramanti S, Vai A, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17(2):242–249. doi:10.1111/tid.12365
   PubMed Web of Science ®Google Scholar
• Dulery R, Malard F, Brissot E, et al. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transplant. 2023;58(11):1215–1222. doi:10.1038/s41409-023-02078-1
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu DP, Liu QF, et al. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019;12(1):88. doi:10.1186/s13045-019-0781-y
   PubMed Web of Science ®Google Scholar
• Al-Homsi AS, Cirrone F, Wo S, et al. PTCy, Abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation. Blood Adv. 2023;7(14):3604–3611. doi:10.1182/bloodadvances.2023010545
   PubMed Web of Science ®Google Scholar
• Watkins B, Qayed M, McCracken C, et al. Phase II trial of costimulation blockade With Abatacept for prevention of acute GVHD. J Clin Oncol. 2021;39(17):1865–1877. doi:10.1200/JCO.20.01086
   PubMed Web of Science ®Google Scholar
• Nakamura M, Meguri Y, Ikegawa S, et al. Reduced dose of PTCy followed by adjuvant alpha-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Sci Rep. 2021;11(1):13125. doi:10.1038/s41598-021-92526-z
   PubMed Web of Science ®Google Scholar
• Dufort G, Castillo L, Pisano S, et al. Haploidentical hematopoietic stem cell transplantation in children with high-risk hematologic malignancies: outcomes with two different strategies for GvHD prevention. Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of experience at a single center. Bone Marrow Transplant. 2016;51(10):1354–1360. doi:10.1038/bmt.2016.161
   PubMed Web of Science ®Google Scholar
• Arnold DE, MacMath D, Seif AE, et al. Immune reconstitution following TCRalphabeta/CD19-depleted hematopoietic cell transplantation for hematologic malignancy in pediatric patients. Transplant Cell Ther. 2021;27(2):169 e1–e9.
   PubMedGoogle Scholar
• Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131(2):247–262. doi:10.1182/blood-2017-05-780668
   PubMed Web of Science ®Google Scholar
• Makanga DR, Guillaume T, Willem C, et al. Posttransplant cyclophosphamide and antithymocyte globulin versus posttransplant cyclophosphamide as graft-versus-host disease prophylaxis for peripheral blood stem cell haploidentical transplants: comparison of T cell and NK effector reconstitution. J Immunol. 2020;205(5):1441–1448. doi:10.4049/jimmunol.2000578
   PubMed Web of Science ®Google Scholar
• Shah RM. Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies. Bone Marrow Transplant. 2021;56(7):1518–1534. doi:10.1038/s41409-021-01246-5
   PubMed Web of Science ®Google Scholar